MIM
BDTX icon

MetLife Investment Management’s Black Diamond Therapeutics BDTX Stock Holding History

MetLife Investment Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-22,286
Closed -$96.9K – 2817
2024
Q3 		$96.9K Buy
22,286
+12,557
+129% +$68.3K ﹤0.01% 2641
2024
Q2 		$45.3K Buy
+9,729
New +$52.2K ﹤0.01% 2771
2021
Q2 		– Sell
-8,148
Closed -$198K – 2441
2021
Q1 		$198K Hold
8,148
– – ﹤0.01% 2056
2020
Q4 		$261K Hold
8,148
– – ﹤0.01% 1836
2020
Q3 		$246K Buy
8,148
+1,831
+29% +$55.7K ﹤0.01% 1731
2020
Q2 		$266K Hold
6,317
– – ﹤0.01% 1729
2020
Q1 		$158K Buy
+6,317
New +$192K ﹤0.01% 1825

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MetLife Investment Management's BDTX Position: Q4 2024 in Review

MetLife Investment Management sold out of Black Diamond Therapeutics (BDTX) in Q4 2024, closing a stake of 22,286 shares — an estimated $96.9K sold.

MetLife Investment Management first reported a position in BDTX in Q1 2020 and held it in 7 quarters. The position peaked at $266K in Q2 2020. 87 funds tracked by Wall St. Rank hold BDTX as of Q4 2024.

  • MetLife Investment Management reported no remaining Black Diamond Therapeutics position as of Q4 2024 after selling out during the quarter.
  • MetLife Investment Management sold 22,286 Black Diamond Therapeutics shares in Q4 2024, an estimated $96.9K.
  • MetLife Investment Management first reported a position in Black Diamond Therapeutics in Q1 2020 and held it in 7 quarters.
  • MetLife Investment Management's Black Diamond Therapeutics position peaked at $266K in Q2 2020.
  • 87 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q4 2024.

Based on MetLife Investment Management's 13F filing for Q4 2024, filed 13 Feb 2025.